ObsEva (CHIX:OBSNZ) Common Stock : CHF8.16 Mil (As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is ObsEva Common Stock?

ObsEva's quarterly common stock increased from Jun. 2022 (CHF6.67 Mil) to Sep. 2022 (CHF8.24 Mil) but then declined from Sep. 2022 (CHF8.24 Mil) to Dec. 2022 (CHF8.16 Mil).

ObsEva's annual common stock increased from Dec. 2020 (CHF4.06 Mil) to Dec. 2021 (CHF5.98 Mil) and increased from Dec. 2021 (CHF5.98 Mil) to Dec. 2022 (CHF8.16 Mil).

ObsEva Common Stock Historical Data

The historical data trend for ObsEva's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Common Stock Chart

ObsEva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

3.39

3.44

4.06

5.98

8.16

ObsEva Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Common Stock	Get a 7-Day Free Trial															5.98	6.33	6.67	8.24	8.16

ObsEva Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

ObsEva (CHIX:OBSNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.obseva.com

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (CHIX:OBSNZ) Headlines

No Headlines